Chugai Pharmaceutical Co., Ltd.
Phone: 81-(0)3-3281-6611
Fax: 81-(0)3-3281-6607
E-mail: Via Site
Web: https://www.chugai-pharm.co.jp
| Native name | 中外製薬株式会社 |
|---|---|
| Romanized name | Chūgai Seiyaku kabushiki gaisha |
| Type | Public KK |
| Traded as |
|
| Industry | Pharmaceutical Industry, Business import, production and development of drugs for medical sales |
| Founded | March 8, 1943 |
| Headquarters | Nihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo On the registration Headquarter: Tokyo Kita (Tokyo) |
| Key people | Osamu Nagayama - Chairman and Tatsuro Kosaka - CEO |
| Revenue | 72.9 billion capital of 47 million yen. Standalone sales of 329.2 billion yen and 344.8 billion yen consolidated (December 2007) |
| Parent | Hoffmann-La Roche (61.62%) |
| Website | www.chugai-pharm.co.jp (in Japanese) |
Chugai's mission is to create innovative drugs for the benefit of patients. As a research-based pharmaceutical company, Chugai specializes in the research, development, production and marketing of prescription pharmaceuticals. We have established the following business processes to create innovative medicines.
For detailed contact information visit location pages below.
Chugai Pharmaceutical Co., Ltd.'s locations around the world
Asia
Clinical Trials sponsored by Chugai Pharmaceutical Co., Ltd.
-
Chugai Pharmaceutical邀请报名抗磷脂综合征 (APS) | 免疫性血小板减少症 (ITP) | 皮肌炎 (DM) | 大疱性类天疱疮 (BP) | 白塞氏综合症 (BS) | 免疫介导的坏死性肌病 (IMNM)匈牙利, 澳大利亚, 日本, 德国, 台湾, 奥地利, 保加利亚, 克罗地亚, 法国, 意大利, 荷兰, 挪威, 葡萄牙, 罗马尼亚, 加拿大, 西班牙, 捷克语, 波兰, 土耳其（türkiye）